Longeveron (NASDAQ:LGVN) Receives Buy Rating from HC Wainwright

HC Wainwright reissued their buy rating on shares of Longeveron (NASDAQ:LGVN) in a report released on Monday,Benzinga reports. HC Wainwright currently has a $10.00 price target on the stock.

Several other research analysts have also commented on the stock. Roth Mkm started coverage on shares of Longeveron in a research note on Friday, December 6th. They set a “buy” rating and a $10.00 price objective for the company. Roth Capital upgraded shares of Longeveron to a “strong-buy” rating in a research note on Thursday, December 5th.

Longeveron Price Performance

Longeveron stock opened at $1.38 on Monday. The stock has a market cap of $20.48 million, a price-to-earnings ratio of -0.22 and a beta of 0.36. Longeveron has a 1 year low of $0.77 and a 1 year high of $6.40. The firm has a 50-day moving average of $1.66 and a two-hundred day moving average of $1.91.

Hedge Funds Weigh In On Longeveron

Hedge funds and other institutional investors have recently modified their holdings of the business. State Street Corp acquired a new stake in Longeveron during the third quarter worth about $29,000. Geode Capital Management LLC increased its position in shares of Longeveron by 316.0% during the third quarter. Geode Capital Management LLC now owns 128,947 shares of the company’s stock valued at $250,000 after acquiring an additional 97,953 shares during the last quarter. Virtu Financial LLC acquired a new stake in shares of Longeveron during the fourth quarter valued at about $53,000. Northern Trust Corp acquired a new stake in shares of Longeveron during the fourth quarter valued at about $31,000. Finally, Jane Street Group LLC purchased a new position in shares of Longeveron in the fourth quarter valued at approximately $35,000. 10.01% of the stock is owned by hedge funds and other institutional investors.

Longeveron Company Profile

Longeveron Inc, a clinical stage biotechnology company, develops cellular therapies for aging-related and life-threatening conditions in the United States and Japan. The company’s lead investigational product is the LOMECEL-B, an allogeneic mesenchymal stem cell formulation sourced from the bone marrow of young and healthy adult donors.